Phase Ib/II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody (AK112) Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Latest Information Update: 08 Jan 2024
At a glance
- Drugs Ivonescimab (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akeso Biopharma
- 08 Oct 2022 Status changed from recruiting to discontinued.
- 19 Aug 2021 New trial record